Federal law, checked in September 2026, did not allow a pharmacy or seller to hand over a prescription drug unless a licensed prescriber had ordered it.
BEFORE CARE / STOP SIGNS
Pause before money or medicine moves
A low price is not enough. Stop when the people, product, or pharmacy cannot be named and checked.
HARD STOPS
Do not explain these away
Some sellers print “research use only” on a product meant for people to inject. FDA warning letters in 2026 said that label did not matter when the seller’s website showed the product was meant for human use.
As of September 2026, any claim that a compounded drug carried FDA approval was untrue, since compounded drugs were not FDA-approved.
As of September 2026, the Federation of State Medical Boards held that a fixed online form alone, where no one can ask follow-up questions, did not meet the standard of care.
COMPOUNDING NOW
Shortage language can be stale
While tirzepatide was in short supply, the shortage was what made it legal for pharmacies to make their own copies.
The FDA had confirmed the national tirzepatide shortage was over in December 2024.
As of September 2026, tirzepatide did not appear on the FDA drug shortage list. It was also not on the FDA list of ingredients that large compounding plants, called outsourcing facilities, may use to make medicine in bulk.
As of September 2026, compounding itself was not always illegal. But federal law let a pharmacy copy a medicine that is already sold only when the prescriber found a change that mattered for that one patient.
A lower price alone did not count as that kind of change.
Ask what exact need the approved product cannot meet. Then ask who made the compounded product.
LAST PASS
Five answers before “yes”
- Clinician: full name and state record
- Product: brand-name or pharmacy-made, pen or vial, and who made it
- Pharmacy: full name and state record
- Price: medicine plus every care fee
- Follow-up: a real human route for questions